The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: James Sidoti - Sidoti & Company - Analyst
: Hi, good afternoon. Can you break out what the COVID, the VTM revenue was in the quarter? I think it was about $200,000 or $300,000. Is that right?
Question: James Sidoti - Sidoti & Company - Analyst
: So down about $1.2 million from a year ago?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JULY 06, 2023 / 3:00PM, TRIB.OQ - Q1 2023 Trinity Biotech PLC Earnings Call
Question: James Sidoti - Sidoti & Company - Analyst
: Okay.
Question: James Sidoti - Sidoti & Company - Analyst
: Okay. You talked a little bit about Kenya, felt like there's a lot of legal hurdle you have to get past. When do you think you'll start shipping product
to Kenya?
Question: James Sidoti - Sidoti & Company - Analyst
: Okay. So, it sounds like you do expect revenue in 2023 from Kenya?
Question: James Sidoti - Sidoti & Company - Analyst
: Got it. And then with the new diabetes instrument, can you give us a little color on when you think those products hit the market?
Question: James Sidoti - Sidoti & Company - Analyst
: And then on --
Question: James Sidoti - Sidoti & Company - Analyst
: Okay. On the autoimmune business, which I believe you said was up about 35% in the quarter, is that the business in upstate New York, the lab
business?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JULY 06, 2023 / 3:00PM, TRIB.OQ - Q1 2023 Trinity Biotech PLC Earnings Call
Question: James Sidoti - Sidoti & Company - Analyst
: So, it sounds like you have multiple areas where you expect things to improve. You just reported Q1 around $15 million. I would imagine you have
a pretty good handle on what you think revenues are for Q2. Can you give us any kind of range where you think revenues come in for the year or
is it still too early to provide guidance?
Question: James Sidoti - Sidoti & Company - Analyst
: Okay. All right. Thank you. That was it for me.
|